Noronha V, Bhattacharjee A, Patil VM, et al. - Given cough is a frequent and distressing symptom in lung cancer patients and a significant reduction in cough frequency with aprepitant (a centrally acting neurokinin-1 inhibitor) has been reported in a pilot study, so, researchers assessed subjective cough improvement as well as quality of life (QoL) and toxicity among patients having advanced lung cancer and cough who were randomized 1:1 to aprepitant 125 mg orally on day one then 80 mg orally on days two to seven with physician’s choice of antitussive; or to physician’s choice of antitussive alone. The participants had a cough lasting over two weeks despite a cough suppressant. At baseline and at day nine, the mean Visual Analog Scale scores (in mm) were found to be 68 and 39 in the aprepitant arm and 62 and 49 in the control arm respectively; and mean Manchester Cough in Lung Cancer Scale scores were 33 and 23 in aprepitant arm and 30 and 25 in control arm, at both the time points. The two arms did not differ significantly in terms of overall QoL, but aprepitant caused a significant improvement in the cough-specific QoL domain. Overall, a significant improvement in cough was brought about by aprepitant in patients with advanced lung cancer, without causing an increase in severe side-effects.